Skip to main content
$10.32 $0.57 (5.8%)

04:00 PM EDT on 09/30/22

Anavex Life Sciences Corp. (NASDAQ:AVXL)

CAPS Rating: 1 out of 5

Current Price $10.32 Mkt Cap $759.9M
Open $9.55 P/E Ratio 0.00
Prev. Close $10.32 Div. (Yield) $0.00 (0.0%)
Daily Range $9.55 - $10.66 Volume 1,047,419
52-Wk Range $7.13 - $23.73 Avg. Daily Vol. 775,053

Caps

How do you think NASDAQ:AVXL will perform against the market?

Add Stock to CAPS Watchlist

All Players

26 Outperform
29 Underperform
 

All-Star Players

2 Outperform
24 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:AVXL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Margaritarius (< 20)
Submitted January 23, 2022

Speculative Pick (2% max allocation would be wise); Sharing my number one stock pick once again; Where many others have failed and gone home, Anavex continues to march towards the first effective treatment for dementia in history; Stock recently fell… More

TMFang4apples (25.92)
Submitted February 19, 2020

Been about 4 years since Anavex raised a heap of money after posting "successful" midstage data. How's that phase 3 Alzheimer's study with 2-73 coming along?

NASDAQ:AVXL Summary

Fools bullish on NASDAQ:AVXL are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about AVXL.

Recs

1
Member Avatar Margaritarius (< 20) Submitted: 1/23/2022 1:02:27 AM : Outperform Start Price: $12.02 NASDAQ:AVXL Score: +2.52

Speculative Pick (2% max allocation would be wise); Sharing my number one stock pick once again; Where many others have failed and gone home, Anavex continues to march towards the first effective treatment for dementia in history; Stock recently fell after they reported positive Phase I results for another candidate in their pipeline (3-71); Investors are too quick to fold their hands; They forget that she is close to completing Phase III testing for her flagship candidate 2-73; 100% of trial study patients have voluntarily signed up for continued treatment under extended long term study protocols since Phase I; Study goals exceed required FDA data points; They’ve also received positive feedback from preliminary FDA reviews with zero change recommendations offered; I predict full FDA approval before year's end; Stock likely to move long before then regardless of what the general market is doing

Recs

2
Member Avatar OklaBoston (45.47) Submitted: 2/19/2020 11:18:35 AM : Outperform Start Price: $5.70 NASDAQ:AVXL Score: +74.64

Shrinking deficit and improving technicals.

Recs

1
Member Avatar TMFang4apples (25.92) Submitted: 2/19/2020 8:57:07 AM : Underperform Start Price: $5.10 NASDAQ:AVXL Score: -95.59

Been about 4 years since Anavex raised a heap of money after posting "successful" midstage data. How's that phase 3 Alzheimer's study with 2-73 coming along?

Leaderboard

Find the members with the highest scoring picks in AVXL.

Score Leader

Under5

Under5 (59.25) Score: +305.36

The Score Leader is the player with the highest score across all their picks in AVXL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Under5 59.25 4/18/2018 5/25/2022 Outperform 5Y $2.13 +383.57% +32.75% +350.82 0 Comment
DorminABC 99.81 3/17/2011 Underperform NS $15.28 -32.59% +180.80% +213.39 0 Comment
conliskjr < 20 11/3/2016 10/18/2021 Outperform 3Y $2.79 +269.18% +72.25% +196.92 0 Comment
SunnySky123 31.57 6/15/2020 Outperform 1Y $3.74 +175.40% +19.54% +155.86 0 Comment
portefeuille 98.18 9/22/2016 Outperform 5Y $3.35 +207.46% +65.62% +141.85 0 Comment
ttkam20 < 20 8/10/2020 Outperform 5Y $4.19 +145.82% +7.25% +138.58 0 Comment
dj8519 25.96 10/26/2020 Outperform 5Y $5.37 +91.81% +5.03% +86.77 0 Comment
OklaBoston 45.47 2/19/2020 3/13/2020 Outperform 3Y $5.70 +80.70% +6.07% +74.64 1 Comment
telecomgirl 88.51 11/10/2015 Outperform 3W $4.20 +145.05% +73.08% +71.98 0 Comment
mdriver78 64.80 11/16/2015 10/22/2020 Outperform 5Y $4.18 +146.42% +74.76% +71.66 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AVXL.